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Abstract 
There is misunderstanding about both the meaning and the role of cost-effectiveness thresholds in 
policy decision making.  This article dissects the main issues by use of a bookshelf metaphor.  Its 
main conclusions are these: 
 
x It must be possible to compare interventions in terms of their impact on a common measure 
of health. 
x Mere effectiveness is not a persuasive case for inclusion in public insurance plans. 
x Public health advocates need to address issues of relative effectiveness. 
x A  ‘ĨŝƌƐƚďĞƐƚ ? benchmark or threshold ratio of health gain to expenditure identifies the least 
effective intervention that should be included in a public insurance plan. 
x The reciprocal of this ratio  W the  ‘ĨŝƌƐƚďĞƐƚ ?cost-effectiveness threshold  W will rise or fall as 
the health budget rises or falls (ceteris paribus). 
x Setting thresholds too high or too low costs lives. 
x Failure to set any cost-effectiveness threshold at all also involves avertable deaths and 
morbidity. 
x The threshold cannot be set independently of the health budget. 
x The threshold can be approached from either the demand-side or the supply side  W the two 
are equivalent only in a health-maximising equilibrium. 
x The supply-side approach ŐĞŶĞƌĂƚĞƐĂŶĞƐƚŝŵĂƚĞŽĨĂ ‘ƐĞĐŽŶĚďĞƐƚ ?cost-effectiveness 
ƚŚƌĞƐŚŽůĚƚŚĂƚŝƐŚŝŐŚĞƌƚŚĂŶƚŚĞ ‘ĨŝƌƐƚďĞƐƚ ?.
x The second best threshold is the one generally to be preferred in decisions about adding or 
subtracting interventions in an established public insurance package. 
x Multiple thresholds are implied by systems having distinct and separable health budgets. 
x Disinvestment involves eliminating effective technologies from the insured bundle. 
x Differential (positive) weighting of ďĞŶĞĨŝĐŝĂƌŝĞƐ ?ŚĞĂůƚŚŐĂŝŶƐŵĂǇŝŶĐƌĞĂƐĞƚŚĞƚŚƌĞƐŚŽůĚ. 
x Anonymity and identity are factors that may affect the interpretation of the threshold. 
x The true opportunity cost of health care in a community, where the effectiveness of 
interventions is determined by their impact on health, is not to be measured in money  W but 
in health itself. 
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Introduction 
The idea of having a cost-effectiveness ratio as a guide for selecting health care interventions for 
inclusion in a national health insurance scheme has proved controversial.  It has a long history (e.g. 
Weinstein and Zeckhauser 1973, Weinstein and Stason 1977, Doubilet 1986, Birch and Gafni 1992, 
Laupacis et al. 1992, George et al. 2001, Towse et al. 2002, Devlin and Parkin 2004, Gafni and Birch 
2006, Culyer et al. 2007, Chambers et al. 2010, Eckermann and Pekarsky 2014, Newall et al. 2014, 
Danzon et al. 2015a and b, Marseille et al. 2015, Culyer 2015).  It is in practical use in some countries 
(e.g. Australia, England and Wales).  It is advocated by significant agencies in wealthy as well as low- 
and middle-income countries (LMICs) (e.g. Office of Health Economics, World Health Organisation) 
and is dismissed as arbitrary and politically repressive by others (Nyhan 2010).  There is 
misunderstanding about both its meaning and its role in decision making. 
 
This article explains the essential meaning of a cost-effectiveness threshold, using the simple 
metaphor of a bookshelf.  Implications of its use, misuse and non-use are explored.  These matters 
are discussed in the context of decisions by governments and agencies concerning the inclusion or 
exclusion of healthcare technologies in public programmes.  To keep matters simple, the 
assumptions made throughout are that insured persons have access to technologies free of charge 
and that the principal objective of such schemes is to promote population health.  The assumption is 
ŵĂŝŶƚĂŝŶĞĚƚŚƌŽƵŐŚŽƵƚƚŚĂƚ “ĞĨĨĞĐƚŝǀĞŶĞƐƐ ?ƌĞůĂƚĞƐƚŽƚŚĞŝŵƉĂĐƚŽĨĂŶŝŶƚĞƌǀĞŶƚŝŽŶŽŶƉĞŽƉůĞ ?Ɛ
health.  This is not to deny that health care systems may have objectives other than health 
maximisation but to focus on what is undoubtedly a major objective1.  The analysis is considered in 
the context of countries of varying degrees of economic development but the main focus is on LMICs 
considering how best to advance universal health coverage (UHC) by introducing a public health 
insurance scheme (PHI). 
 
What treatments should be included in public insurance schemes? 
The World Health Organisation (WHO) defines as  ‘essential ? "those drugs that satisfy the health care 
needs of the majority of the population; they should therefore be available at all times in adequate 
amounts and in appropriate dosage forms, at a price the community can afford" (WHO 2003).  This is 
a curious definition, partly because it contains a value judgment to the effect that such drugs ought 
to be provided and an ambiguous condition that they be provided only at a price the community in 
question can afford.  In practice the WHO has a long list of  ‘essential ? drugs but leaves it up to local 
 ‘communities ? to determine which ones are to feature on their local list.  In practice, then, whether a 
medicine is  ‘essential ?, and therefore provided at all times in adequate amounts and appropriate 
dosages, depends on whether a local community chooses to afford it. 
 
One such community is Tanzania, whose current essential list contains more than 500 medicines 
with many controversial drugs on it such as Avastin in addition to Taxol and Paraplatin for treating 
ovarian cancer, and Lucentis for treating macular eye disease (Tanzania Ministry of Health and Social 
Welfare 2013, p 279).  The first of these is regarded as not cost-effective by NICE in England and 
Wales at approximately £144,000 ($206,000) per Quality-Adjusted Life-Year (QALY) and the second 
is recommended only if the manufacturer offers substantial discounts (NICE 2013 a, b).  They stand, 
ŶŽŶĞƚŚĞůĞƐƐ ?ŽŶdĂŶǌĂŶŝĂ ?ƐůŝƐƚŽĨĐŽƐƚ-effective  ‘essential ? medicines.  
                                                          
1
 Other objectives commonly include financial protection (e.g. from the out-of-pocket expense of costly interventions), 
reassurance, information provision (e.g. diagnostic utility), certification (e.g. for legitimate absence from work), reduction 
in uncertainty (e.g. ĂďŽƵƚŽŶĞ ?ƐĞǆƉŽƐƵƌĞƚŽŚĞĂůƚŚƌŝƐŬƐ ) ?ƐŽĐŝĂůƐŽůŝĚĂƌŝƚǇ ?social or national iconography (e.g. when a 
ŚĞĂůƚŚĐĂƌĞƐǇƐƚĞŵƌĞƉƌĞƐĞŶƚƐƚŚĞ “ŬŝŶĚŽĨƉĞŽƉůĞǁĞĂƌĞ ? ) ?support for manufacturing and innovation in supply chain 
industries, and even provision of ineffective but popularly demanded treatments (e.g. ďǇƚƌĂĚŝƚŝŽŶĂůŚĞĂůĞƌƐ ? ‘ĂůƚĞƌŶĂƚŝǀĞ ?
medicine, religion-driven interventions). Evidently not all of these objectives are in direct conflict with the enhancement of 
population health. Neither do they all have equal merit. 
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What counts as  ‘cost-effective ? that this can be so?  Tanzania seems to apply a threshold of 
acceptability that is even higher than the range recommended by the WHO.  The WHO deems an 
intervention offering a unit of health gain (usually a DALY averted) at a cost under three times GDP 
per capita ($7,300 in Tanzania) to be  ‘relatively cost-effective ? and one with a cost per unit of 
outcome less than GDP per capita ($2,400 per capita in Tanzania) to be  ‘highly cost-effective ?.  These 
are already high, even though in Tanzania they would exclude Avastin if the WHO guidance were to 
be followed.  A currently available estimate of a plausible range for the threshold in Tanzania is $45-
$912 (Woods 2015).  The serious (as distinct from tokenistic) adoption of these high thresholds 
ǁŽƵůĚƌĂƉŝĚůǇĞǆŚĂƵƐƚdĂŶǌĂŶŝĂ ?ƐŚĞĂůƚŚďƵĚŐĞƚƐ ?ďŽƚŚƉƌŝǀĂƚĞĂŶĚƉƵďůŝĐ ?ĂŶĚůĞĂǀĞŵĂŶǇŵƵĐŚ
more cost-effective interventions ?ǁŝƚŚŵƵĐŚŵŽƌĞŝŵƉĂĐƚŽŶƚŚĞĐŽƵŶƚƌǇ ?ƐŚĞĂůƚŚƐƚĂƚus per dollar, 
unfunded. 
 
Why it is so wrong for countries to adopt (mostly implicitly) thresholds that acknowledge too many 
interventions as being worth having?  Why is it wrong for the WHO to recommend very high cost-
effectiveness thresholds as criteria for selecting interventions in public insurance systems, especially 
in poor countries?2 And how might one set about selecting a responsible threshold? 
 
The bookshelf 
 
Figure 1 The range of interventions 
 
Imagine a bookshelf such as that in Figure 1  W a very long bookshelf  W of health care interventions, 
each like a book, and ranked according to its effectiveness (its height), with the most effective on the 
left and the less effective stretching away on the right.  Some interventions are disease specific like 
the cancer treatments just mentioned; some are not disease specific, like interventions to improve 
childhood nutrition; while others, like community clinics or community health workers, are general 
delivery platforms or common generic resources available for many diseases and interventions.  In 
all cases, however, we need some acceptable common measure or indicator of the contribution that 
each intervention makes to health.  It must be common, like change in mortality or longevity, or 
QALYs or DALYs, in order for decision makers to be able to make comparisons of the productivity of 
                                                          
2
 Or even as targets that rich countries have an asserted duty to enable them to implement (a duty unlikely to be 
recognised by many countries). 
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each.  If they cannot make reasonable comparisons they can hardly make reasonable choices.  This 
may seem a self-evident point.  However, nearly all (or at any rate a very large number of) the 
studies of the effectiveness of interventions for health in LMICs have measures of outcome that 
ensure comparisons cannot be made.  
 
The fatness of each book represents the estimated cost of providing it.  This is a combination of the 
costs of a specific technology, such as a drug, the costs of associated procedures (other medicines, 
diagnostic services, community services, etc.) for as long as the treatment continues, and the 
estimated number of people using the intervention in question.  A population health promoter will 
select the first book on the left and add books (that is, further interventions) moving along the shelf 
until the agency runs out of the money the government has allocated to health, or subscribers have 
subscribed at current insurance premium rates.  At that point all the interventions selected will be 
effective and only the most effective of those that are effective will have been selected.  The only 
services offered under the NHI plan are those to the left.  The least cost-effective intervention that is 
in the plan indicates a threshold of to. 
 
 
Figure 2 The budget and the threshold 
 
Higher productivity per dollar is equivalent to lower cost per unit of health outcome.  The numerator 
here is health or health gain and the denominator cost.  The heights of the books on the shelf, in 
other words, are the reciprocals of the familiar cost-effectiveness ratios in which the numerator is 
cost and the denominator is health or health gain. 
 
Why are all effective interventions not in the insured bundle? 
The reason why the interventions on the right are not included is not because they are ineffective.  
On the contrary, they are all effective.  One would have to go a long way to the right before hitting 
zero productivity or slipping into the zone of iatrogenesis.  The trouble with them is that they are not 
effective enough.  If the benchmark test for inclusion of further interventions is the cost-
effectiveness of the least cost-effective intervention that is included in the plan, to, then they are not 
cost-effective enough either.  It immediately follows that merely to demonstrate the effectiveness of 
an intervention is not enough to ensure its inclusion in the insured bundle.  From the viewpoint of 
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population health there are simply better ways of using the budget.  Of course, were the budget to 
be increased, then further interventions could be added, but this takes us into the realm of  ‘meso ? 
cost-effectiveness, in which we have to make a judgment about the costs to other public 
programmes or to private consumption as resources were switched to health and a further 
judgment is then required as to their value where they are relative to the value of the expected 
increase in health if they were switched3.  Public health advocates, to be effective, need therefore to 
demonstrate relative effectiveness.  One way of doing this is to make direct comparisons between 
interventions, such as comparing alternative treatments for cancer or for macular degeneration.  A 
less cumbersome procedure is to use the threshold, and make comparisons with that.4  
 
The threshold and the budget are intimately linked 
The determinants of the threshold are fundamentally three: the underlying demographics and 
disease burden, which affects the productivity of interventions (if that rises, the threshold t rises); 
local environments, customs and values (which affect health and commercial behaviours and the 
ǀĞƌǇŶŽƚŝŽŶŽĨ ‘ŚĞĂůƚŚ ?ĂŶĚŚĞŶĐĞĂŐĂŝŶƚŚĞƉƌŽĚƵĐƚŝǀŝƚǇŽĨ ŝŶƚĞƌǀĞŶƚŝŽŶƐ); and the budget (if that 
were to fall, t rises).  In summary, the threshold depends on (a) the productivity of interventions and 
(b) the size of the budget.  We can see this in the figures.  First consider a fall in the budget, ceteris 
paribus.  The budget line moves to the left in Figure 3 and the threshold rises to t1.  Now there are 
fewer types of intervention in the insured bundle. 
 
 
Figure 3 Budget falls and threshold rises 
 
Or let the budget rise. The vertical budget line moves to the right in Figure 4 and the threshold falls 
to t2.  The variety of interventions rises. 
                                                          
3
 A more general set of sectoral thresholds is implied with effectiveness defined in terms of a more general indicator of 
well-ďĞŝŶŐ ?ƐƵĐŚĂƐ “ƵƚŝůŝƚǇ ? (an indicator of social or collective strength of preference). 
4
 We abstract, as previously stated, from the effectiveness of interventions of all kinds on the non-health objectives of 
health care systems and their budgets. 
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Figure 4 Budget rises and threshold falls 
 
The threshold is not determined only by per capita GDP, which is but one of the determinants, nor is 
it appropriate to link it in linear fashion to GDP per capita.  However, since health care spending has 
a positive income elasticity, rising incomes enable proportionately higher health budgets and 
countries with higher incomes to have proportionately higher health spending (see Woods et al., 
2015, for some multi-country estimates).  One way of looking at the threshold is nonetheless as a 
demand concept  W an implication of a collective willingness to pay for health as expressed by the size 
of the health budget.  This can be contrasted with a supply-side view which is mentioned later. 
 
Choosing badly kills 
dŚĞŵŽƌĂůŝƚǇŽĨƉƌŽƉĞƌƵƐĞŽĨĂƚŚƌĞƐŚŽůĚĐŽŵĞƐĨƌŽŵŝƚƐŝŵƉĂĐƚŽŶƉĞŽƉůĞ ?ƐŚĞĂůƚŚ ?ǁŚŝĐŚǁĞƚĂŬĞ
as having a moral worth that usually trumps that of non-health objectives of health care systems.  If 
interventions on the right of the threshold are allowed to replace any on its left, population health 
falls.  In Figure 5 books on the shelf have been swapped from either side of the budget line.  The 
hatched area is the loss of life and/or quality of life from having the wrong things in the plan.  
Decision makers are typically ignorant as to whether they have the right things assigned to either 
side of the vertical budget line (Eckermann and Pekarsky 2014) but so long as they always replace 
interventions having lower productivity per dollar with ones that have higher productivity per dollar, 
they will be moving in the right direction and, if they also ensure that those that are included have a 
productivity per dollar that is higher than to, then they can be confident of extracting even more 
health from their health dollars. 
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Figure 5 Health loss from poor technology selection 
 
There is the converse: if the low productivity intervention is already in the bundle, then the hatched 
area represents the health gain from eliminating it and replacing it with the more productive 
technology on the right.  Note the politically difficult and somewhat counterintuitive fact: 
disinvestment, even in effective technologies, can increase health. 
 
First best and second best 
The analysis has been purposefully simplified.  It has been assumed that all decision makers want is 
to have as great an impact on population health as possible.  We have assumed that decisions are 
taken in and apply for a single accounting period.  Another assumption is that each intervention is 
not internally ranked, as when a procedure is more effective for some types of patient than others, 
so that some applications of it may be high while others were low in the ranking  W and some of them 
perhaps even lie on the other side of the borderline.  Yet another simplification is that the measure 
of effectiveness is indifferent to the characteristics of the people who gain or lose: an extra year of 
life or an extra QALY is of equal value whoever gets it.  These are all assumptions that can be 
addressed in specific situations and modified as necessary. 
 
A simplification having deeper consequences is that all the interventions on the left are more 
productive than all those on the right.  If decision makers are planning ahead for a public health 
insurance plan that is yet to be established using consistent health promoting principles and there is 
no historical encumbrance of bad past decisions, then they can have some confidence that the 
interventions selected are more cost-effective than those left out. In this case the assumption is not 
only descriptively idealistic, it is also realistic.  /ƚƌĞƉƌĞƐĞŶƚƐĂ ‘ĨŝƌƐƚďĞƐƚ ? situation.  It is a 
commonplace of welfare economics, however, ƚŚĂƚƚŚĞƌĞƐŽƵƌĐĞĂůůŽĐĂƚŝŽŶ ‘ƌƵůĞƐ ?ĚĞƌŝǀĞĚƵŶĚĞƌ
such circumstances may not be appropriate when these assumptions do not apply (Lipsey and 
Lancaster 1956).  /ŶƐƵĐŚĐĂƐĞƐƚŚĞƚŚĞŽƌǇŽĨ ‘ƐĞĐŽŶĚďĞƐƚ ?ŝƐƌĞƋƵŝƌĞĚ ? If now the starting point is 
the historical inheritance of a set of insured interventions whose evidential base was poor or left 
unexplored, many of which were selected for reasons other than a plausibly demonstrated highly 
effective impact on population health, then it is evidently more likely for the insured set to include 
procedures less effective per dollar than some of those excluded, so less health is lost per dollar 
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when they are displaced.  The estimated (second best) threshold under these circumstances will be 
lower (the threshold incremental cost-effectiveness ratio will be higher).  Put another way, 
introducing a new intervention into an already established health care package entails, given a 
constant budget, a greater chance of disinvesting in low productivity interventions, so the real 
opportunity cost of new interventions is lower.  Put more generally, the more internally efficient the 
health system at any given budget, the higher the opportunity cost of additions to the insured 
bundle. 
 
The empirical work of Claxton and colleagues (2015) does not make the first best simplifying 
assumptions but estimates the displacement of interventions, when new ones come in and the 
budget remains constant, in terms of the actual interventions that are dispensed with regardless of 
their relative productivity.  There is no guarantee, for example, that those displaced are the least 
productive interventions.  They may be simply those that are managerially the most convenient in 
the short run to remove or reduce.  However, they indicate the health loss associated with the 
introduction of a new technology, or its opportunity cost in terms of health.  To the extent that this 
opportunity cost is lower than the loss of the most marginal technology in a first best allocation of 
the same budget, the second best threshold will appear lower than the first best threshold (the 
incremental cost-effectiveness ratio will be higher (Eckermann and Pekarsky 2014)).  This is a supply-
side and behavioural approach to the threshold, which gives an estimate that equals the first best 
threshold only when the system is in  ‘equilibrium ? at a health-maximising optimum, and the least 
cost-effective technologies are relatively easy to identify.  The method is likely to yield an estimate 
of opportunity cost (health lost) lower than under the first best allocation of the same budget  W how 
much of an underestimate will depend on the ability of health service commissioners (purchasers) 
and managers to identify the least-cost technologies that lie within their discretion to eliminate.  
More importantly, the second best threshold is the appropriate one to use in decisions about 
revising the content of an established insured bundle since it embodies an estimate of the actual 
opportunity cost.  A specific value of this approach is that, data permitting, it enables decision 
makers to identify with some degree of precision which interventions may be eliminated at least 
cost in terms of their contribution to population health. 
 
The implication that the second best cost-effectiveness threshold will typically be higher than the 
first best threshold should not obscure the fact that an actual cost-effectiveness threshold in use 
may be too high.  For example, Claxton et al. (2014) suggest quite strongly that the actual thresholds 
used by NICE inn England and Wales are too high. 
 
Orphan diseases and an ethical dilemma 
Finally, it has also been assumed that making a maximum impact on health is the only objective of 
NHI or UHC.  That is obviously not true.  One ought at least to add in equity, or distributive fairness 
and financial protection, as other criteria.  However, these complications would clutter the ability of 
the simple model to yield insights.  In particular, decision makers need to be alert to the implication 
that any departure from the bookshelf principle on whatever grounds costs lives, or at least the 
quality of lives.  Departures need, therefore, a strong ethical case.  
 
Suppose that the reason for swapping the two books in Figure 5 lay in the distributional 
characteristics of each: perhaps the low productivity intervention is a very costly but not very 
effective treatment for an orphan disease.  One has natural humanitarian empathy with patients 
suffering from diseases like cystic fibrosis, muscular dystrophy, Gaucher's disease, ,ƵŶƚŝŶŐĚŽŶ ?Ɛ
disease, ,ƵŶƚĞƌ ?Ɛ^ǇŶĚƌŽŵĞŽƌ WŽŵƉĞ ?ƐĚŝƐĞĂƐĞ.  But decision makers need to be clear that in 
replacing a more productive intervention with the orphan treatment, they are causing others to lose 
lives  W or the quality of lives, or both.  That may be an acceptable trade-off but a trade-off it is and 
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one ought not to imagine that attending to other health policy priorities than having the maximum 
impact on health comes cheap.  It is often thought that it is humanitarian to support expensive but 
not very effective interventions for people with orphan diseases  W but it seems not at all humanitarian 
if to do so mindlessly ignores the health losses imposed on others.  This is not to suggest that 
decision makers ought to lack sympathy for hard cases, only that they should not ditch logic in 
exercising their sympathy.  What is especially tricky about such cases is also that the identity, or at 
least the characteristics, of a proposed favoured minority group (the orphan disease victims) is 
known, whereas that of those who lose, whose services are no longer provided from the fixed 
budget, is not.  They are usually anonymous  W and easily overlooked.  So a further ethical question 
thus arises  W are costs falling on invisible people to be ignored or given a lower weight by virtue of 
their invisibility? They may even be people with whom decision makers would have no less 
sympathy than the sympathy they have for those with orphan diseases. 
 
The threshold in low- and middle-income countries 
One of the sad truths about health and health care in LMICs is that policy makers are constantly 
bombarded with claims  W many from health economists and public health physicians  W for the 
inclusion of interventions whose only virtue is that they are effective.  Childhood interventions, 
particularly vaccinations, often provide greatest value.  In sub-Saharan Africa, for example, rotavirus 
vaccination has been associated with a cost-per-DALY-averted of $43 (Atherly et al. 2009) and 
treatment of severe malnutrition costs $53 per DALY-averted (Bachmann 2010).  Even within HIV, 
prevention of mother-to-child HIV transmission costs below $150 per DALY-averted using available 
interventions (Shah et al. 2011).  All of these are likely to be cost-effective choices for countries like 
Tanzania, yet a large coverage gap remains across all low- and middle-income countries (UNAIDS 
2013, Revill et al. 2015).  These high-impact and highly cost-effective interventions are seriously 
under-provided, while advocates routinely make recommendations on the basis of excessively high 
cost-effectiveness thresholds, or none at all, aiming to promote access in poor communities to new 
and more expensive therapies with cost-effectiveness ratios 100 times worse than these (Chisholm 
et al. 2012, Ortegon et al. 2012).  
 
What, then, are the consequences of trying to apply such thresholds?  
 
 
Figure 6 Threshold too low for the given budget 
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A cost-effectiveness threshold that is too high is a health gain per dollar threshold that is too low.  
We can see what is likely to happen by returning to the bookshelf.  In Figure 6 there is the same 
array of books as before, for which the threshold was to.  Setting the threshold at tlow is appropriate 
for a health budget much larger than the one in the figure.  It will admit into the insured bundle the 
additional interventions shown by the arrows.  What will happen? In the absence of a further, more 
rational criterion (e.g. a supplementary threshold of to), the outcome is likely to be an arbitrary set of 
interventions.  In an extreme case, the most productive interventions will be replaced by the least 
productive ones.  That is shown by the hatched area in Figure 7.  An arbitrary selection of the 
threshold, which is typically too high, loses lives. 
 
 
Figure 7 Extreme health loss from threshold set too low 
 
The contrary phenomenon will occur when the threshold is set too high for the budget.  This is 
shown in Figure 8.  With thigh and the budget as before, all the technologies indicated by the arrows 
are omitted from the insured package with the consequential loss of life and quality of life shown by 
the hatched area.  The offence to health is compounded by the needless holding back of available 
funding. 
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Figure 8 Health loss from threshold too high 
 
Asymmetries in investing and disinvesting 
One ought not to underestimate the problems, mainly political, of pressures to invest in 
interventions that are too costly and that drive out those that are more cost-effective.  An 
intervention that is adopted generates incomes for its manufacturers, its prescribers and is usually 
gratefully received by its patients.  It has a massive interest already vested in it.  The same is less true 
of those that have yet to be approved, which are in direct competition with others yet to be 
approved, where all the gains are as yet prospective and not as yet vested.  It nonetheless remains 
that the threshold is what marks the boundary between the more and the less cost-effective 
treatments, given a particular planned rate of expenditure on health care.  Any other threshold is 
arbitrary and harmful to health, notwithstanding the interests (doubtless very vocal) that may be 
vested in it. 
 
The  ‘second best ? threshold is, however, indisputably hard to estimate, even approximately.  
Unfortunately, it is also tremendously easy to propose aspirational (Revill et al. 2015) thresholds 
that are far too high.  These thresholds all implicitly assume that the fraction of GDP that should go 
on health and health care is much larger than it actually is.  They are an implicit form of advocacy.  
The problem with cost-effectiveness thresholds that are too high is that they define as cost-
effective, or even highly cost-effective, treatments that, if implemented, would more than exhaust 
the available budget and crowd out treatments that deliver more health gain per dollar.  At best 
ƚŚĞǇĐĂŶƉƌŽǀŝĚĞĂŬŝŶĚŽĨ ‘ůŽŶŐůŝƐƚ ?ŽĨŝŶƚĞƌǀĞŶƚŝŽŶƐĨŽƌĨƵƌƚŚĞƌĐŽŶƐŝĚĞƌĂƚŝŽŶ ? One therefore needs 
a more realistic supplementary cost-effectiveness threshold to select from the long list: one that is 
realistic given the circumstances and budget of the country in question.  But then why bother with 
the long list in the first place? The basic truth is that in setting the budget in any country, decision 
makers thereby also set the threshold, or in setting the threshold they imply the budget.  They ought 
never to set the one without realizing that in so doing they imply the other.  
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Multiple thresholds? 
Some jurisdictions may in the short term have more than one threshold (Danzon et al. 2015b).  For 
example, South Africa has in essence two parallel systems: the private insurance/private provision 
sector and the public insurance/public provision one.  In the short term it makes sense to set a cost-
effectiveness threshold for the public sector that is lower than the one implicitly or explicitly set for 
the private sector.  The main challenge then becomes how best to manage the harmonisation of the 
two over time.  (A further significant challenge is how to explain the rationale for dual thresholds to 
the public and professionals).  Tanzania might prudently set a specific threshold for its  ‘essential ? 
drugs list while it searches for a more general threshold for system-wide application, and a method 
again of harmonizing the two over time.  Some LMICs could have multiple thresholds to reflect the 
reality that donor funding, for example, has focused on specific disease areas like malaria or 
HIV/AIDS, where the marginal productivity of disease-specific interventions per dollar has fallen 
below that of other forms of intervention (say, nutrition).  The point in having multiple thresholds is 
to avoid, not to perpetuate, investments that are not having the greatest possible impact on 
population health, by identifying where the best pay-offs lie and to signal the necessary shifts in 
resource allocation. 
 
Differential weights on outcomes and the threshold 
The standard application of the principle of horizontal justice requires that people who are alike in 
some ethically relevant sense be treated alike.  There has arisen a concern in some quarters for 
departing from the usual assumption that a  ‘QALY is a QALY is a QALY ? in favour of weighting QALYs 
received by those near the end of life more heavily (Paulden et al. 2014, Claxton et al. 2015, McCabe 
et al. 2015).  Making such adjustments, whether on these grounds or any other, has implications for 
the threshold itself.  Paradoxically, increasing the weight attached to particular technologies in order 
for them to pass the threshold test can also increase the threshold itself.  Take the end-of-life case.  
A candidate technology is particularly to be used for patients near the end of their lives.  Supposing 
the closeness to death to be the only ethically relevant differentiating feature, then ethical 
consistency requires that all end-of-life cases receive similar weights, including those receiving 
treatments that are already in the insured bundle.  Suppose further that the weighting accorded the 
candidate technology is sufficient for it to fall below the existing cost-effectiveness threshold.  The 
impact on the threshold depends upon the distribution of end-of-life patients across the 
technologies in the insured bundle.  If they are users of the least productive (the marginal) 
technology in the bundle, then its effective (weighted) productivity also increases and the cost-
effectiveness threshold therefore falls.  If it increases sufficiently relative to the next most 
productive technology, that technology may become the marginal treatment, to be displaced in 
whole or in part by the new technology.  If, on the other hand, such patients are distributed across 
the inframarginal technologies in the bundle, then the marginal technology remains unchanged and 
so does the threshold.  The candidate technology displaces the existing marginal technology.   
 
The point is that, whatever the merits or otherwise of favouring such groups in considering the 
introduction of new interventions, similar groups exist elsewhere within the same health care 
system and are actually receiving current treatments for other conditions.  The consequences for 
them as they are denied services will need normally to be taken into account on grounds of ethical 
consistency.  A judgment has therefore to be reached as to the distribution of such patients across 
existing insured treatments and the consequential quantitative impact of the differential weights on 
the threshold. 
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What is my threshold? 
Failure to set a threshold, whether or not it is publicly declared, can have similar consequences to 
setting one that systematically admits too many low productivity interventions.  If jurisdictions 
deliberately fail to use a threshold they should probably stop pretending that that they are trying to 
have the maximum impact on their ƉĞŽƉůĞ ?ƐŚĞĂůƚŚ ? Many countries are shy about being explicit 
about thresholds (Canada, the USA).  Federal structures are easily capable of permitting the 
simultaneous existence of multiple thresholds (one for each province or state or public programme), 
mostly implicit rather than explicit.  All are ways of ensuring that population health is not maximised. 
 
One way of avoiding setting tŚƌĞƐŚŽůĚƐĂƐƉŝƌĂƚŝŽŶĂůůǇŝƐƚŽ ‘threshold search ? (Culyer et al 2007) by 
identifying the least cost-effective intervention currently provided and the most cost-effective 
intervention not yet routinely available.  This approach might be suited to a two- or multi-threshold 
country.  There are a reasonable number of available economic evaluations that are probably 
generalizable and applicable in most jurisdictions.  One might investigate the cost-effectiveness of 
interventions falling just inside and just outside the insured bundle in various jurisdictions and 
triangulate towards a reasonable approximation to  ‘ƐĞĐŽŶĚďĞƐƚ ?threshold.  Yet another approach, 
appropriate for countries with very low public expenditures, is to proceed pragmatically with self-
evidently cost-effective programmes, with scaling-up determined judgmentally, but evaluating each 
scale-up and each newly added intervention so that over, say, a five year period sufficient 
information became available about the cost-effectiveness of the programmes being supported and 
the pressure on budgets.  The cost-effectiveness of the least cost-effective programme being 
supported then becomes a provisional threshold and new programmes with lower cost-effectiveness 
would not be recommended.  
 
Another possibility is to conduct low-cost small scale pilot studies of prima facie highly cost-effective  
interventions which could then be scaled up or not as and when their efficiency is confirmed or 
disconfirmed.  The Thais have been good at this (e.g. Teerawattananon et al. 2009, 
Teerawattananon et al. 2014). 
 
Yet another approach is to estimate the productivity of health care expenditure across countries.  
Multi-country panel data show that health outcomes improve as countries increase spending on 
health care, although at a diminishing rate.  Understanding this relationship could indicate which 
interventions are likely to increase or reduce productivity in the health sectors of different 
jurisdictions with particular levels of resources and healthcare needs.  
 
The most complete approach, where the data exist to implement it, is the supply-side method 
developed by Claxton et al. (Claxton et al. 2015).  This econometric work does not make the 
simplifying assumption that no technology in use has a lower productivity than the threshold, and 
exploits the existence of programme budgets in the National Health Service.  These cover 23 
budgets.  Differences in them can be linked to differences in mortality and, with some further 
assumptions, to QALYs.  The central estimate of the threshold using this method for 2008 
expenditure and 2008 W10 mortality was £12,936 per QALY, well below the threshold range of £20k-
30k used by NICE. 
 
Aiding not replacing thought and judgment 
However, perfect precision is not in general required.  What is needed is an understanding of the 
meaning of the threshold and some idea of its likely order of magnitude in any given context.  The 
purpose of this information is to inform thought and judgment, not to replace either.  The 
epidemiological science is always contestable, the endpoints of trials are rarely far enough off, what 
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is demonstrably efficacious may not be effective, the coverage of costs is often incomplete, 
substantial uncertainty attaches to many key variables, full scientific consensus is rare.  The cost-
effectiveness of most interventions (inside and outside an insured bundle) remains conjectural.  The 
evidence therefore never speaks for itself.  In any case, judging what to include in the insured bundle 
cannot be solely based on evidence, even if it is good evidence (Culyer 2014) because a decision also 
depends upon the objectives set for the health care system and on the value judgments embodied in 
the criteria for including or excluding treatments in or from the insured bundle (Rawlins and Culyer 
2004).  But aids to better judgment are valuable, provided they are understood and the science 
supporting them is honest science.  They are valuable, not only because they increase the chance 
that good decisions will be made but also because they nearly always involve the participation of 
ŽƚŚĞƌƐƚŚĂŶ ‘ĞǆƉĞƌƚƐ ? ?thereby gaining public credibility, ĂŶĚďĞĐĂƵƐĞƚŚĞƉƌŽĐĞƐƐŽĨĞǆĞƌĐŝƐŝŶŐŽŶĞ ?Ɛ
judgment, provided it is not conducted in secrecy, can be publicly defended and can lead to a public 
media and a citizenry that also understands and judges in an informed way. 
 
/ŶƐƵŵŵĂƌǇ ? 
We started with the simple idea that more health is a good thing and then showed that to achieve 
more health  
 
x it must be possible to compare interventions in terms of their impact on a common 
measure of health;  
x mere effectiveness is not a persuasive case for inclusion in public insurance plans; 
x public health advocates need to address issues of relative effectiveness if they are to be 
more effective advocates for public health; 
x a  ‘ĨŝƌƐƚďĞƐƚ ?benchmark or threshold ratio of health gain to expenditure identifies the 
least effective intervention that should be included in a public insurance plan; 
x the reciprocal of this ratio  W the cost-effectiveness threshold  W will rise or fall as the 
health budget rises or falls (ceteris paribus); 
x setting thresholds too high or too low costs lives; 
x failure to set a cost-effectiveness threshold also involves avertable deaths and 
morbidity; 
x the threshold cannot be set independently of the health budget; 
x what is cost-effective in one jurisdiction may be cost-ineffective in another (depending 
on the budget, local prices and costs, disease burden and local values); 
x the threshold can be approached from either the demand-side or the supply side; 
x the two are equivalent only in a health-maximising equilibrium; 
x the supply-ƐŝĚĞĂƉƉƌŽĂĐŚŐĞŶĞƌĂƚĞƐĂŶĞƐƚŝŵĂƚĞŽĨĂ ‘ƐĞĐŽŶĚďĞƐƚ ?ƚŚƌĞƐŚŽůĚƚŚĂƚŝƐ
ŚŝŐŚĞƌƚŚĂŶƚŚĞ ‘ĨŝƌƐƚďĞƐƚ ? ? 
x the  ‘second best ? threshold is the one generally to be preferred in decisions about 
adding or subtracting interventions in an established public insurance package; 
x multiple thresholds are implied by systems having distinct and separable health 
budgets; 
x disinvestment involves eliminating effective technologies from the insured bundle; 
x ĚŝĨĨĞƌĞŶƚŝĂů ?ƉŽƐŝƚŝǀĞ )ǁĞŝŐŚƚŝŶŐŽĨďĞŶĞĨŝĐŝĂƌŝĞƐ ?ŚĞĂůƚŚŐĂŝŶƐŵĂǇŝŶĐƌĞĂƐĞƚŚĞ
threshold; 
x anonymity and identity are factors that may affect the interpretation of the threshold.  
 
Finally, and implicitly throughout, the true opportunity cost of health care in a community, where 
the effectiveness of interventions is determined by their impact on health, is not to be measured in 
money  W but in health itself. 
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